CD3+
CD3+ refers to cells that express the cluster of differentiation 3 (CD3) glycoprotein complex, a surface antigen expressed on the majority of T lymphocytes and a critical component of the T cell receptor (TCR) signaling machinery.
CD3+ refers to cells that express the cluster of differentiation 3 (CD3) glycoprotein complex, a surface antigen expressed on the majority of T lymphocytes and a critical component of the T cell receptor (TCR) signaling machinery. As an essential marker of T cell identity and function, CD3 plays a fundamental role in T cell development, thymic selection, and antigen-driven T cell activation. Beyond its developmental significance, CD3 has emerged as a major therapeutic target in immuno-oncology, particularly through the design of bispecific and multispecific antibodies that redirect T cells toward tumor cells expressing specific tumor-associated antigens. These CD3-engaging therapeutics, known as T cell engagers, include BiTEs (bispecific T cell engagers), which leverage the inherent cytotoxic capacity of T cells to generate durable anti-tumor responses.
Where the papers sit
13 papers from the last 6 months study CD3+ directly · updated from PubMed 28 Sept 2026
Study type 4 clinical trials · 3 observational · 1 human data · 5 preclinical
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Bispecific T-Cell Engagers
CD3-directed engagers are expanding from BCMA targeting toward multispecific and affinity-tuned designs for hematologic and solid tumors. DNA hypomethylating agents may preserve T-cell stemness and improve bispecific activity, while local EpCAM, IL-12 and GM-CSF mRNA delivery seeks systemic control from intratumoral treatment. FAP×CD3 and TCR-mimic constructs extend targeting to solid-tumor antigens, with evidence mainly from preclinical or ex vivo models. Clinical translation, dosing and the durability of tumor control remain open.
7 papers · 53.8%
-
Myeloma Bispecific Therapy
CD3 bispecifics are moving deeper into relapsed or refractory myeloma treatment, with teclistamab and talquetamab also being tested in combinations such as talquetamab-daratumumab. Cytokine release syndrome, infections and prolonged B-cell depletion recur across treatment experience. GPRC5D-directed talquetamab adds distinctive toxicities that require active recognition and management, while pharmacovigilance is broadening safety signals beyond trials. Earlier-line use and safer sequencing remain unresolved.
4 papers · 30.8%
-
B-ALL Relapse Prevention
Blinatumomab is being integrated around allogeneic transplantation to redirect donor lymphocytes against B-ALL and strengthen graft-versus-leukemia activity. Pretransplant exposure is associated with lower relapse and better disease-free survival in adults undergoing transplant. Periallotransplant BiTE use aims to preserve this antileukemic benefit while limiting treatment burden and immune complications. The balance with graft-versus-host disease, including chronic disease, and the need for prospective confirmation remain open.
2 papers · 15.4%
CD3 redirection can control tumors through immune and stromal remodeling, not only direct killing of antigen-bearing tumor cells
The FAP×CD3 engager OMTX305 in patient-derived lung and ovarian cancer tumor slices and intratumoral EpCAM BITE combined with IL-12 and GM-CSF mRNA-LNPs in bilateral human xenograft tumors both depart from the assumption that CD3 engagement works principally by directly lysing targeted tumor cells. OMTX305 instead eliminated FAP-expressing fibroblasts and triggered bystander killing of adjacent tumor cells, while the EpCAM strategy expanded T-cell activity in both injected and distant untreated tumors and induced HLA class II programs that could make cancer cells antigen-presenting. Together, these findings shift the therapeutic frame toward CD3-driven remodeling of the tumor microenvironment and propagation of antitumor immunity beyond the initially engaged target cells. 42726846Sep 42696537Sep
CD3 expression is proposed as a genetically mediated immune regulator of primary aldosteronism
The FES eQTL study in primary aldosteronism and TD CD8br immune cells assigns CD3 a role distinct from its use as the T-cell-engaging arm of anticancer bispecifics. Using Mendelian randomization, colocalization, and mediation analyses, it associated FES expression with CD3 expression on TD CD8br cells and linked increased CD3 expression with reduced risk of primary aldosteronism. This places CD3 within a putative immune-genetic pathway influencing endocrine disease risk rather than solely within therapeutic T-cell redirection. 42115443May
Papers
The 13 papers from the last 6 months that study CD3+ directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Bispecific T-Cell Engagers (7)
- The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
- Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors. Proceedings of the National Academy of Sciences of the United States of America · 4 Sept 2026 PMID 42696537
- Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
- TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. Signal transduction and targeted therapy · 24 Jun 2026 PMID 42342658
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
- Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
- FES eQTL suppresses the progression of primary aldosteronism by regulating CD3 on TD CD8br immune cells: Mendelian randomization and mediation analysis. Mammalian genome : official journal of the International Mammalian Genome Society · 11 May 2026 PMID 42115443
Myeloma Bispecific Therapy (4)
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
- Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology (Amsterdam, Netherlands) · 1 Sept 2026 PMID 42679119
- Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine · 15 Jun 2026 PMID 42294841
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
B-ALL Relapse Prevention (2)
- Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
- "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Blood advances · 20 May 2026 PMID 42160762
By study type
Clinical trials (4)
- Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience. Hematology (Amsterdam, Netherlands) · 1 Sept 2026 PMID 42679119
- Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. The New England journal of medicine · 15 Jun 2026 PMID 42294841
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. The New England journal of medicine · 29 May 2026 PMID 42212933
- Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients. Clinical pharmacology and therapeutics · 28 May 2026 PMID 42206665
Observational studies and case reports (3)
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
- Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
- "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL. Blood advances · 20 May 2026 PMID 42160762
Human data, design not indexed (1)
- FES eQTL suppresses the progression of primary aldosteronism by regulating CD3 on TD CD8br immune cells: Mendelian randomization and mediation analysis. Mammalian genome : official journal of the International Mammalian Genome Society · 11 May 2026 PMID 42115443
Preclinical: animal, cell and lab studies (5)
- The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
- Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors. Proceedings of the National Academy of Sciences of the United States of America · 4 Sept 2026 PMID 42696537
- Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion. mAbs · 20 Aug 2026 PMID 42619408
- TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy. Signal transduction and targeted therapy · 24 Jun 2026 PMID 42342658
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-08-12. Last written: 2026-09-17 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.